A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
Clinical trial NCT06465550 · RECRUITING
Trial details
- NCT number
- NCT06465550
- Sponsor
- Shanghai BDgene Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-05
- Primary completion
- 2026-12-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.